Caris Life Sciences (NASDAQ:CAI) Shares Gap Up Following Better-Than-Expected Earnings

Shares of Caris Life Sciences, Inc. (NASDAQ:CAI) gapped up prior to trading on Friday following a stronger than expected earnings report. The stock had previously closed at $19.24, but opened at $21.16. Caris Life Sciences shares last traded at $21.32, with a volume of 1,119,366 shares trading hands.

The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.27. The company had revenue of $292.89 million during the quarter, compared to analysts’ expectations of $281.00 million. During the same quarter last year, the firm posted ($1.73) earnings per share. The firm’s revenue was up 125.4% on a year-over-year basis.

Key Caris Life Sciences News

Here are the key news stories impacting Caris Life Sciences this week:

• Positive Sentiment: Q4 beat and strong top-line growth — Caris reported GAAP EPS of $0.28 (vs. $0.01 consensus) and revenue of ~$292.9M, up ~125% YoY, which supports near-term revenue momentum. Caris Q4 results and conference materials
• Positive Sentiment: Interim Achieve 1 readout boosts MCED thesis — The company announced an interim readout showing Caris Detect (WGS + AI) demonstrated superior sensitivity and specificity versus methylation-based approaches, a milestone de‑risking the MCED launch potential and long-term revenue upside. Caris Achieve 1 interim readout
• Positive Sentiment: Analyst initiation/upgrade activity — Robert W. Baird initiated coverage with an Outperform rating and raised its price target (from $26 to $28), adding institutional validation that helped lift sentiment. Baird initiates coverage Benzinga: PT raise
• Positive Sentiment: FY‑2026 revenue guidance centered near $1.0B — Management guided to roughly $1.0B–$1.02B for 2026 (above consensus of ~$995.8M), which supports a bullish growth narrative. Q4 & full‑year results and 2026 outlook
• Positive Sentiment: Product innovation — Caris added an AI‑powered breast cancer signature to its molecular reporting, strengthening its diagnostic/clinical utility toolkit and potential addressable market. AI breast cancer signature
• Neutral Sentiment: Premarket trading reaction noted in coverage — Reports flagged premarket gains after the earnings/achieve readout, reflecting immediate positive sentiment but not guaranteeing sustained momentum. Benzinga premarket report
• Neutral Sentiment: Short-interest data is noisy/uninformative in filings — February short-interest entries showed anomalous/zero values and are not a reliable signal at the moment.
• Negative Sentiment: Analyst PT trim from BTIG — BTIG cut its price target from $45 to $38 while keeping a buy rating; the downward revision reduces upside from some long‑term models even though the new PT still implies material upside. Benzinga: BTIG PT cut

Analyst Upgrades and Downgrades

A number of brokerages recently commented on CAI. BTIG Research decreased their target price on shares of Caris Life Sciences from $45.00 to $38.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings reissued a “sell (d)” rating on shares of Caris Life Sciences in a research note on Monday, December 29th. Robert W. Baird raised their price target on Caris Life Sciences from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Friday. Canaccord Genuity Group increased their price objective on Caris Life Sciences from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Monday, December 22nd. Finally, Wall Street Zen downgraded shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $33.50.

Insider Activity at Caris Life Sciences

In other news, insider Luke Thomas Power sold 62,250 shares of Caris Life Sciences stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $26.58, for a total transaction of $1,654,605.00. Following the sale, the insider owned 99,571 shares of the company’s stock, valued at approximately $2,646,597.18. The trade was a 38.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.80% of the company’s stock.

Institutional Investors Weigh In On Caris Life Sciences

Several hedge funds have recently added to or reduced their stakes in CAI. PointState Capital LP boosted its stake in Caris Life Sciences by 73.0% in the 4th quarter. PointState Capital LP now owns 6,718,707 shares of the company’s stock worth $181,271,000 after purchasing an additional 2,834,986 shares in the last quarter. UBS Group AG raised its holdings in Caris Life Sciences by 825.9% in the 4th quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock worth $58,924,000 after acquiring an additional 1,948,107 shares during the last quarter. Balyasny Asset Management L.P. boosted its stake in Caris Life Sciences by 23,902.9% during the 4th quarter. Balyasny Asset Management L.P. now owns 1,660,280 shares of the company’s stock valued at $44,794,000 after purchasing an additional 1,653,363 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Caris Life Sciences by 185.0% in the 4th quarter. JPMorgan Chase & Co. now owns 2,445,281 shares of the company’s stock worth $65,974,000 after purchasing an additional 1,587,176 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its holdings in shares of Caris Life Sciences by 14.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 9,205,959 shares of the company’s stock valued at $248,377,000 after purchasing an additional 1,180,200 shares in the last quarter.

Caris Life Sciences Trading Up 11.3%

The company has a quick ratio of 9.36, a current ratio of 9.93 and a debt-to-equity ratio of 0.79. The firm has a market cap of $6.04 billion and a P/E ratio of -46.54. The stock has a fifty day moving average price of $24.58.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.